We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01108497
Recruitment Status : Terminated
First Posted : April 22, 2010
Last Update Posted : June 24, 2016
Sponsor:
Information provided by (Responsible Party):
Stanford University

Brief Summary:
We will study gene and protein expression in leukemia cells of children diagnosed with acute leukemia. We hope to identify genes or proteins which can help us grade leukemia at diagnosis in order to: (a) develop better means of diagnosis and (b) more accurately choose the best therapy for each patient.

Condition or disease Intervention/treatment
Leukemia Procedure: Bone Marrow Aspiration

Study Type : Observational
Actual Enrollment : 235 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia
Study Start Date : July 2001
Primary Completion Date : September 2015
Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia
U.S. FDA Resources




Primary Outcome Measures :
  1. Gene Expression [ Time Frame: days 0, 8, 22 or 29 ]

Biospecimen Retention:   Samples With DNA
bone marrow


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible.
Criteria

Inclusion Criteria:1. All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible. There is no bias in regards to age range, gender or ethnic background.

2. Signed informed consent


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01108497


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Norman James Lacayo Stanford University

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01108497     History of Changes
Other Study ID Numbers: PEDSHEM0001
11062 ( Other Identifier: Stanford IRB )
SU-09112009-3881 ( Other Identifier: Stanford University )
First Posted: April 22, 2010    Key Record Dates
Last Update Posted: June 24, 2016
Last Verified: June 2016

Additional relevant MeSH terms:
Leukemia
Neoplasms by Histologic Type
Neoplasms